Gastroenterology· Topic 5.9 Cirrhosis, liver failure, and transplantation· 5.9.13

Solid organ transplant complications

Solid organ transplant complications arise from the immunosuppression that prevents graft rejection, producing a predictable, time-dependent pattern of rejection, opportunistic infection, and malignancy. Diagnosis rests on allograft biopsy and pathogen-specific testing, and first-line treatment pairs targeted therapy of the complication with a deliberate adjustment, not blanket discontinuation, of the immunosuppressive regimen.

12 min read2 practice questions8 key factsSubscriber article
  • Topic review
    The full article, organized the way the exam asks it.
  • ABIM-format MCQs
    Vignettes with an explanation for every wrong answer.
  • Key facts
    The numbers and thresholds worth memorizing, up front.
  • AI tutor
    MedBrain answers the question you're stuck on.

What this article covers

  • Overview

    Solid organ transplant complications are the predictable result of the immunosuppression that keeps a kidney, liver, heart, or lung graft from being rejected.

  • Epidemiology

    Kidney is the dominant graft type, so most complication data come from kidney recipients, though the same principles apply across organs.

  • Risk factors

    HLA mismatch and prior sensitization: fewer shared HLA alleles raises rejection risk, and prior transfusion, pregnancy, or transplantation can generate preformed anti-HLA antibodies that raise antibody-mediated rejection risk.

  • Pathophysiology

    Rejection is classified by timing and mechanism.

  • Clinical features

    Hyperacute rejection: graft ischemia and thrombosis within minutes of vascular anastomosis, the organ mottled and failing to perfuse on the table.

  • Differential diagnosis

    T-cell-mediated acute rejection: interstitial lymphocytic infiltrate with tubulitis on biopsy, but antibody-mediated rejection shows microvascular inflammation and a positive donor-specific antibody titer.

  • Diagnosis

    What establishes the diagnosis: allograft biopsy is the gold standard for rejection, distinguishing T-cell-mediated from antibody-mediated disease; for infection, quantitative nucleic acid…

  • Management

    First, adjust immunosuppression: for BK nephropathy and PTLD, stepwise reduction is the primary intervention, balanced against precipitating rejection.

  • Complications

    Graft failure: the end point of unresolved rejection, requiring dialysis or organ-specific supportive care and evaluation for retransplantation.

  • Prognosis

    Modern immunosuppression has improved outcomes: graft failure from rejection has decreased as regimens and pretransplant HLA and antibody screening have improved.

  • Prevention

    CMV prophylaxis: valganciclovir 900 mg PO once daily for 3 to 6 months (100 to 200 days) in at-risk recipients, particularly D+/R- pairings, or equivalent pre-emptive therapy triggered by rising viral load.

Read the whole article

Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.